Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DCGONASDAQ:PTWONASDAQ:SERANASDAQ:TOI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDCGODocGo$1.59-1.9%$1.76$1.23▼$5.68$162.15M0.95785,281 shs1.17 million shsPTWOPono Capital Two$11.00+1.0%$11.45$8.04▼$36.52$57.42M-0.0127,253 shs12,700 shsSERASera Prognostics$1.92+2.1%$2.32$1.37▼$9.13$72.33M0.72153,557 shs248,155 shsTOIOncology Institute$2.39+0.4%$2.72$0.13▼$3.50$213.27M0.131.04 million shs2.39 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDCGODocGo0.00%+9.66%+18.66%-40.45%-49.20%PTWOPono Capital Two0.00%0.00%0.00%0.00%-19.30%SERASera Prognostics0.00%+12.28%+2.13%-49.34%-73.59%TOIOncology Institute0.00%-3.24%-20.07%+139.91%+487.08%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDCGODocGo2.2624 of 5 stars3.32.00.00.01.92.50.6PTWOPono Capital TwoN/AN/AN/AN/AN/AN/AN/AN/ASERASera Prognostics0.4516 of 5 stars0.02.00.00.01.82.50.0TOIOncology Institute2.1878 of 5 stars3.55.00.00.00.01.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDCGODocGo 2.50Moderate Buy$3.56123.90% UpsidePTWOPono Capital Two 0.00N/AN/AN/ASERASera Prognostics 0.00N/AN/AN/ATOIOncology Institute 3.00Buy$7.00192.89% UpsideCurrent Analyst Ratings BreakdownLatest PTWO, DCGO, TOI, and SERA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025TOIOncology InstituteBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$7.005/12/2025DCGODocGoCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$5.00 ➝ $1.455/9/2025DCGODocGoNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$4.00 ➝ $3.005/9/2025DCGODocGoBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral4/8/2025DCGODocGoNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.00(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDCGODocGo$616.55M0.26$0.42 per share3.76$3.09 per share0.51PTWOPono Capital TwoN/AN/A$0.10 per share114.25($1.68) per shareN/ASERASera Prognostics$80K904.08N/AN/A$1.40 per share1.37TOIOncology Institute$393.41M0.54N/AN/A$0.05 per share47.80Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDCGODocGo$19.99M-$0.02N/A19.88N/A-0.12%2.52%1.70%8/6/2025 (Estimated)PTWOPono Capital Two$340KN/A0.00∞N/AN/A-68.16%-5.23%N/ASERASera Prognostics-$32.90M-$0.94N/AN/AN/A-28,685.22%-51.35%-37.21%8/6/2025 (Estimated)TOIOncology Institute-$64.66M-$0.70N/A∞N/A-15.38%-445.02%-34.13%8/12/2025 (Estimated)Latest PTWO, DCGO, TOI, and SERA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025SERASera Prognostics-$0.24-$0.20+$0.04-$0.20$0.06 million$0.04 million5/14/2025Q1 2025TOIOncology InstituteN/A-$0.18N/A-$0.21N/A$104.41 million5/8/2025Q1 2025DCGODocGo-$0.01-$0.09-$0.08-$0.09$104.25 million$96.03 million3/24/2025Q4 2024TOIOncology Institute-$0.08-$0.14-$0.06-$0.14$109.15 million$100.27 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDCGODocGoN/AN/AN/AN/AN/APTWOPono Capital TwoN/AN/AN/AN/AN/ASERASera PrognosticsN/AN/AN/AN/AN/ATOIOncology InstituteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDCGODocGoN/A2.442.44PTWOPono Capital TwoN/A0.320.32SERASera PrognosticsN/A2.022.02TOIOncology Institute14.581.791.59Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDCGODocGo56.44%PTWOPono Capital Two60.82%SERASera Prognostics54.64%TOIOncology Institute36.86%Insider OwnershipCompanyInsider OwnershipDCGODocGo2.70%PTWOPono Capital Two63.90%SERASera Prognostics15.80%TOIOncology Institute8.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDCGODocGo4,407101.98 million99.23 millionOptionablePTWOPono Capital TwoN/A5.22 million1.88 millionNot OptionableSERASera Prognostics12037.67 million31.72 millionOptionableTOIOncology Institute66089.23 million81.65 millionNot OptionablePTWO, DCGO, TOI, and SERA HeadlinesRecent News About These CompaniesApprovals for oncology procedures rise under Ayushman Bharat Arogya Karnataka schemeJune 10, 2025 | timesofindia.indiatimes.comThe Oncology Institute, Inc. (NASDAQ:TOI) Director Sells $232,788.20 in StockJune 10, 2025 | insidertrades.comJane Street Group LLC Has $39,000 Holdings in The Oncology Institute, Inc. (NASDAQ:TOI)June 10, 2025 | marketbeat.comThe Oncology Institute, Inc. (NASDAQ:TOI) Director Sells $232,788.20 in StockJune 9, 2025 | marketbeat.comInsider Selling: The Oncology Institute, Inc. (NASDAQ:TOI) Director Sells 673,676 Shares of StockJune 9, 2025 | marketbeat.comInsider Selling: The Oncology Institute, Inc. (NASDAQ:TOI) Director Sells 1,976,137 Shares of StockJune 6, 2025 | insidertrades.comBrad Hively Sells 1,976,137 Shares of The Oncology Institute, Inc. (NASDAQ:TOI) StockJune 5, 2025 | marketbeat.comThe Oncology Institute set to join the Russell 2000® and Russell 3000® IndexesJune 3, 2025 | globenewswire.comShort Interest in The Oncology Institute, Inc. (NASDAQ:TOI) Increases By 26.4%June 3, 2025 | marketbeat.comOncology Institute (NASDAQ:TOI) Trading Up 2.9% - Time to Buy?May 31, 2025 | marketbeat.comInsider Selling: The Oncology Institute, Inc. (NASDAQ:TOI) Director Sells 203,532 Shares of StockMay 23, 2025 | insidertrades.comOncology Institute First Quarter 2025 Earnings: US$0.25 loss per share (vs US$0.22 loss in 1Q 2024)May 16, 2025 | finance.yahoo.comOncology Institute Shares Rise After Higher 1Q RevenueMay 15, 2025 | marketwatch.comThe Oncology Institute Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 GuidanceMay 15, 2025 | finanznachrichten.deTOI reaffirms 2025 guidance with $460M–$480M revenue target as capitation contracts fuel growthMay 15, 2025 | msn.comQ1 2025 Oncology Institute Inc Earnings CallMay 15, 2025 | finance.yahoo.comThe Oncology Institute, Inc. (TOI) Q1 2025 Earnings Call TranscriptMay 15, 2025 | seekingalpha.comThe Oncology Institute Welcomes Dr. Jeff Langsam as Chief Clinical OfficerMay 14, 2025 | globenewswire.comTopicus.com Inc. Announces Election of Members of the Board of DirectorsMay 13, 2025 | globenewswire.comThe Oncology Institute to Participate at the B. Riley Securities 25th Annual Institutional Investor ConferenceMay 13, 2025 | globenewswire.comWhy The Oncology Institute, Inc.’s (TOI) Stock Is Down 5.48%May 10, 2025 | aaii.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePTWO, DCGO, TOI, and SERA Company DescriptionsDocGo NASDAQ:DCGO$1.59 -0.03 (-1.85%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.64 +0.04 (+2.83%) As of 06/20/2025 06:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.DocGo Inc. provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services. It also offers mobile health services through its platform that are performed at home, offices, and other locations; event services, which include on-site healthcare support at sporting events and concerts; and total care management solutions comprising healthcare services and ancillary services, such as shelter. DocGo Inc. was founded in 2015 and is headquartered in New York, New York.Pono Capital Two NASDAQ:PTWOPono Capital Two, Inc. does not have any significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. Pono Capital Two, Inc. was incorporated in 2022 and is based in Honolulu, Hawaii.Sera Prognostics NASDAQ:SERA$1.92 +0.04 (+2.13%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.77 -0.15 (-7.76%) As of 06/20/2025 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.Oncology Institute NASDAQ:TOI$2.39 +0.01 (+0.42%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$2.47 +0.08 (+3.35%) As of 06/20/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies. It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
